Recombinate (Hemophilia A and B) – Forecast and Market Analysis to 2022
The competitive landscape of hemophilia A and B recombinant therapy in the US and 5EU is dominated by the use of recombinant FVIII and FIX replacement factors, and patients with severe forms of the disease receive frequent prophylactic infusions beginning from the first one or two years of life and often continuing through adulthood. However, the burden on patients and their families to maintain the prophylactic treatment schedule is high, and there is a significant unmet need for new therapies that can reduce the number of weekly prophylactic infusions and alleviate some of this treatment burden.
Baxter’s Recombinate is a first-generation recombinant Factor VIII replacement therapy for hemophilia A patients. It is produced in CHO cells that express full-length recombinant FVIII. However, unlike Advate, Recombinate is produced in cells that are grown in the presence of human and animal serum as well as stabilized in human albumin.
Complete report available @ http://www.rnrmarketresearch.com/recombinate-hemophilia-a-and-b-forecast-and-market-analysis-to-2022-market-report.html
Scope
• Overview of Hemophilia A and B, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
• Detailed information on Recombinate including product description, safety and efficacy profiles as well as a SWOT analysis.
• Sales forecast for Recombinate for the top nine countries from 2012 to 2022.
• Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan, Argentina and China.
Request a Sample @ http://www.rnrmarketresearch.com/contacts/request-sample?rname=145254
Reasons to buy
• Understand and capitalize by identifying products that are most likely to ensure a robust return
• Stay ahead of the competition by understanding the changing competitive landscape for Hemophilia A and B
• Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
• Make more informed business decisions from insightful and in-depth analysis of Recombinate performance
• Obtain sales forecast for Recombinate from 2012-2022 in top nine countries (the US, France, Germany, Italy, Spain, the UK, Japan, Argentina and China)
Buy a copy of report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=145254
For further information on “Recombinate (Hemophilia A and B) – Forecast and Market Analysis to 2022” report OR for any other business research / market intelligence need on the “Hematology Therapeutics” (http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics/hematology-therapeutics ), Contact sales@rnrmarketresearch.com / Call +1 888 391 5441.
